Only HIV-negative people should use PrEP. An HIV test is required before starting PrEP and then every 3 months while taking it. The document discusses a pilot program called Targeted PrEP Implementation Program (TPIP) that provided PrEP to high-risk HIV-negative men who have sex with men and transgender women. It evaluates the program and provides data on participant demographics, enrollment numbers, adherence rates, reasons for discontinuing PrEP, and STI diagnosis rates.

1. Only people who are HIV-
negative should use PrEP.
An HIV test is required
before starting PrEP and
then every 3 months while
taking PrEP.
18-24 25-34 35-44
45-54 55+ Unknown
Targeted PrEP Implementation Program­Draft
DATA
COLLECTION
● Determine the extentto which
PrEP can be implemented in
“real world” settings
● AssisttheAIDS Institute (AI) in
identifying needed resources to
enable routine use ofPrEP
● Laythe foundation forstatewide
program implementation, where
PrEP is delivered as partofa
comprehensive prevention plan
Data Brief #1 January 2016
PROGRAM
ELIGIBILITES
● Be male sexatbirth
● Be the age of18 years orolder
● Be a gayman orMSM/transgender
woman
● Have an HIV-seronegative status
● Exhibitevidence ofhigh-riskbehavior
foracquisition ofHIVinfection
● Be willing to provide contact
information
● Be informed aboutprogram
requirements and be willing to
participate as indicated
Intake, eligibility, and medical visit:
● Assess and determine client’s
eligibilityatintake
● Collectclientmedical visitdata at1st,
3rd, 6th, 9th, and 12th month visit
Demographicand STI testing data:
● Match TPIP clients records toAIDS
Institute Reporting System for
demographicand STI results
PURPOSE
What is Pre­Exposure Prophylaxis (PrEP)?
PrEP is a new HIV
prevention method in
which people who do not
have HIV infection take a
pill daily to reduce their risk
of becoming infected.
RX PrEP can only be
prescribed by a health
care provider and must
be taken as directed to
work.
Client Demographics (N=171)
White Black Hispanic
Asian Other Unknown
Male Transgender woman
Unknown
60%
2%2%
9%
13%
14%
46%
3%
18%
12%
19%
2%
5%
In 2013, the New York State Department of Health (NYSDOH) AIDS Institute initiated a pilot PrEP program
targeting HIV-negative men who have sex with men (MSM) and transgender females at high risk for HIV
infection. The one-year program was a collaboration between NYSDOH and five community medical providers*
designed to gain practical knowledge and understanding of the opportunities and challenges associated with
implementing PrEP in the community. This data brief is the first of a series of three that highlights the key
findings from a multiple-component evaluation of TPIP.
*Trillium Health, APICHA, Evergreen Health Services, William F. Ryan CHC, SUNY Downstate.
Targeted PrEP Implementation Program (TPIP)
93%
PrEP
Race/
Ethnicity Age Gender
2%

2. 198Assessed for TPIP
171 enrolled in TPIP
5 no showafterIntake
22 ineligible/chose notto start
41 Discontinued
9 at1stmonth 4 at9th month
10 at6th month
17 at3rd month 1 at12th month
9
17
10
4
1
2 at1stmonth 8 at6th month
10 at3rd month 13 at9th month
33 Lost to follow up
6 3
5
2
1
5
Reasons Why Clients
Stopped Taking PrEP (N=41)
HIV­ Positive/
Acute HIV/PEP
20
1
1
2
6
7Insurance issues
Client chose not to
start PrEP
Client is low risk
Client lost to
follow­up/
relocated
Client did not
complete labs
Requested
to stop
Decreased risk
behaviors
Client relocated
Insurance issues
Non­adherent
Side effects
HIV­ Positive*
171
22
5
10
2
8
13
4
STI Diagnosis
Baseline
Gonorrhea
Chlamydia
Syphilis
6th
Month
12th
Month
Newly
diagnosed
Positive atIntake
and 12th month
visit
1
3
6
9
12
(N=163)
(N=150)
(N=124)
(N=86)
(N=36)
Number of
clients
reporting
51
18
10
2
0
Medical Visit
Month
Reported Side Effects by
Month
* Clientwas exposed to HIVprior
to Intake buttested negative at
Intake.
70
21
16
1
0
Reasons Why Clients Were
Not Enrolled in TPIP (N=22)
Number of
side effects
reported
Client Enrollment
Contact: 1­800­541­AIDS
Website: http://www.health.ny.gov/diseases/aids/
Revised: December 24, 2015 ­ Draft Version
Produced: The Office of Program Evaluation and Research
Adherence* rate during the program
ranged from 91.0% ­ 94.1%
* Taking 4 or more doses of PrEP medication
in the week prior to medical visit